Abstract 3675: Novel immune oncology strategy for targeted cytotoxic lymphocyte activation
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3675
Abstract: High-dose interleukin 2 (IL2) therapy was the first FDA-approved immunotherapy, and still has an exceptionally high true long-term cure rate for metastatic cancer. However, IL2 therapy has fallen out of favor due to systemic toxicity… read more here.
Keywords: therapy; oncology; omcp mutil2; mutil2 ... See more keywords